NASDAQ:ADVM Adverum Biotechnologies (ADVM) Stock Price, News & Analysis $2.21 -0.02 (-0.90%) Closing price 04:00 PM EasternExtended Trading$2.20 -0.01 (-0.45%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Adverum Biotechnologies Stock (NASDAQ:ADVM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADVM alerts:Sign Up Key Stats Today's Range$2.10▼$2.2250-Day Range$2.05▼$5.6052-Week Range$1.78▼$10.14Volume212,597 shsAverage Volume268,855 shsMarket Capitalization$46.17 millionP/E RatioN/ADividend YieldN/APrice Target$26.40Consensus RatingModerate Buy Company OverviewAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Read More… Adverum Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreADVM MarketRank™: Adverum Biotechnologies scored higher than 76% of companies evaluated by MarketBeat, and ranked 239th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingAdverum Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAdverum Biotechnologies has only been the subject of 3 research reports in the past 90 days.Read more about Adverum Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adverum Biotechnologies are expected to decrease in the coming year, from ($4.92) to ($5.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adverum Biotechnologies is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adverum Biotechnologies is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdverum Biotechnologies has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adverum Biotechnologies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.67% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Adverum Biotechnologies has recently increased by 3.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdverum Biotechnologies does not currently pay a dividend.Dividend GrowthAdverum Biotechnologies does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.78 Percentage of Shares Shorted10.67% of the float of Adverum Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdverum Biotechnologies has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Adverum Biotechnologies has recently increased by 3.50%, indicating that investor sentiment is decreasing. News and Social Media1.9 / 5News Sentiment0.44 News SentimentAdverum Biotechnologies has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Adverum Biotechnologies this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ADVM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Adverum Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Adverum Biotechnologies insiders have bought 3,216.83% more of their company's stock than they have sold. Specifically, they have bought $863,040.00 in company stock and sold $26,020.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Adverum Biotechnologies is held by insiders.Percentage Held by Institutions48.17% of the stock of Adverum Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adverum Biotechnologies' insider trading history. Receive ADVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address ADVM Stock News HeadlinesAdverum Biotechnologies, Inc. (NASDAQ:ADVM) CEO Sells $18,252.00 in StockMay 17, 2025 | insidertrades.comAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Major Shareholder Purchases $149,000.00 in StockApril 25, 2025 | insidertrades.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 23, 2025 | Porter & Company (Ad)Q2 Earnings Forecast for ADVM Issued By HC WainwrightMay 20 at 2:05 AM | americanbankingnews.comQ3 Earnings Estimate for ADVM Issued By HC WainwrightMay 18, 2025 | americanbankingnews.comAdverum Biotechnologies' (ADVM) "Buy" Rating Reiterated at Chardan CapitalMay 18, 2025 | americanbankingnews.comAdverum Biotechnologies (NASDAQ:ADVM) Receives Buy Rating from HC WainwrightMay 18, 2025 | americanbankingnews.comRoyal Bank of Canada Lowers Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $4.00May 17, 2025 | americanbankingnews.comSee More Headlines ADVM Stock Analysis - Frequently Asked Questions How have ADVM shares performed this year? Adverum Biotechnologies' stock was trading at $4.67 at the beginning of 2025. Since then, ADVM stock has decreased by 52.7% and is now trading at $2.21. View the best growth stocks for 2025 here. How were Adverum Biotechnologies' earnings last quarter? Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its quarterly earnings results on Tuesday, April, 15th. The biotechnology company reported ($1.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by $0.62. When did Adverum Biotechnologies' stock split? Shares of Adverum Biotechnologies reverse split before market open on Thursday, March 21st 2024. The 1-10 reverse split was announced on Thursday, March 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Adverum Biotechnologies' major shareholders? Adverum Biotechnologies' top institutional shareholders include BML Capital Management LLC (13.13%), Principia Wealth Advisory LLC (8.16%), Goldman Sachs Group Inc. (2.21%) and Pale Fire Capital SE (1.76%). Insiders that own company stock include Braden Michael Leonard, Laurent Fischer, Peter Soparkar, Setareh Seyedkazemi, Brigit Riley, James Paul Scopa and Richard Beckman. View institutional ownership trends. How do I buy shares of Adverum Biotechnologies? Shares of ADVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adverum Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adverum Biotechnologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings4/15/2025Today5/23/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADVM CIK1501756 Webwww.adverum.com Phone(650) 656-9323Fax650-329-8151Employees190Year FoundedN/APrice Target and Rating Average Stock Price Target$26.40 High Stock Price Target$40.00 Low Stock Price Target$4.00 Potential Upside/Downside+1,094.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($6.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,170,000.00 Net MarginsN/A Pretax Margin-9,524.40% Return on Equity-65.14% Return on Assets-40.52% Debt Debt-to-Equity RatioN/A Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual Sales$1 million Price / Sales46.17 Cash FlowN/A Price / Cash FlowN/A Book Value$8.26 per share Price / Book0.27Miscellaneous Outstanding Shares20,891,000Free Float19,928,000Market Cap$46.17 million OptionableOptionable Beta1.03 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ADVM) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.